Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies.

King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Prah P, Jit M, Edmunds WJ, Sonnenberg P.

Br J Cancer. 2015 Mar 19. doi: 10.1038/bjc.2015.90. [Epub ahead of print]

PMID:
25791874
2.

Quantifying Parameter and Structural Uncertainty of Dynamic Disease Transmission Models Using MCMC: An Application to Rotavirus Vaccination in England and Wales.

Bilcke J, Chapman R, Atchison C, Cromer D, Johnson H, Willem L, Cox M, Edmunds WJ, Jit M.

Med Decis Making. 2015 Jan 26. pii: 0272989X14566013. [Epub ahead of print]

PMID:
25623063
3.
4.

Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy.

Verguet S, Johri M, Morris SK, Gauvreau CL, Jha P, Jit M.

Vaccine. 2015 Mar 3;33(10):1291-6. doi: 10.1016/j.vaccine.2014.11.050. Epub 2014 Dec 23.

5.

Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach.

van Kleef E, Green N, Goldenberg SD, Robotham JV, Cookson B, Jit M, Edmunds WJ, Deeny SR.

J Hosp Infect. 2014 Dec;88(4):213-7. doi: 10.1016/j.jhin.2014.08.008. Epub 2014 Sep 18.

PMID:
25441017
6.

Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".

Newall AT, Jit M, Hutubessy R.

Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0. No abstract available.

PMID:
25374292
7.

Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.

Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagón T, Brisson M.

Vaccine. 2014 Oct 7;32(44):5845-53. doi: 10.1016/j.vaccine.2014.07.099. Epub 2014 Aug 12.

8.

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.

Jit M, Brisson M, Portnoy A, Hutubessy R.

Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2. Epub 2014 Jun 9.

9.

Reassessing the value of vaccines.

Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani FN, Hutubessy R, Jamison DT, Jha P, Jit M, Johnson H, Laxminarayan R, Lee BY, Mhatre S, Mills A, Nordström A, Ozawa S, Prosser L, Silver K, Benn CS, Standaert B, Walker D.

Lancet Glob Health. 2014 May;2(5):e251-2. doi: 10.1016/S2214-109X(13)70170-0. Epub 2014 Apr 23. No abstract available.

10.

Nosocomial transmission of C. difficile in English hospitals from patients with symptomatic infection.

van Kleef E, Gasparrini A, Guy R, Cookson B, Hope R, Jit M, Robotham JV, Deeny SR, Edmunds WJ.

PLoS One. 2014 Jun 16;9(6):e99860. doi: 10.1371/journal.pone.0099860. eCollection 2014.

11.

Evaluating the potential risks and benefits of infant rotavirus vaccination in England.

Clark A, Jit M, Andrews N, Atchison C, Edmunds WJ, Sanderson C.

Vaccine. 2014 Jun 17;32(29):3604-10. doi: 10.1016/j.vaccine.2014.04.082. Epub 2014 May 9.

PMID:
24814524
12.

Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.

Newall AT, Jit M, Hutubessy R.

Pharmacoeconomics. 2014 Jun;32(6):525-31. doi: 10.1007/s40273-014-0162-x.

PMID:
24791735
13.

Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination.

Quinn E, Jit M, Newall AT.

Expert Rev Pharmacoecon Outcomes Res. 2014 Jun;14(3):425-35. doi: 10.1586/14737167.2014.908713. Epub 2014 Apr 16. Review.

PMID:
24734967
14.

Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?

Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M.

Vaccine. 2014 May 30;32(26):3237-42. doi: 10.1016/j.vaccine.2014.03.098. Epub 2014 Apr 13.

PMID:
24726246
15.

An integrated approach to evaluating alternative risk prediction strategies: a case study comparing alternative approaches for preventing invasive fungal disease.

Sadique Z, Grieve R, Harrison DA, Jit M, Allen E, Rowan KM; FIRE Study Investigators.

Value Health. 2013 Dec;16(8):1111-22. doi: 10.1016/j.jval.2013.09.006. Epub 2013 Nov 11.

PMID:
24326164
16.

The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy.

Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E.

J Infect. 2014 Apr;68(4):363-71. doi: 10.1016/j.jinf.2013.11.013. Epub 2013 Dec 1.

17.

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.

Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, Beddows S, Gill ON.

Vaccine. 2013 Dec 17;32(1):26-32. doi: 10.1016/j.vaccine.2013.10.085. Epub 2013 Nov 6.

18.

Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents.

Choi HC, Leung GM, Woo PP, Jit M, Wu JT.

Vaccine. 2013 Dec 17;32(1):78-84. doi: 10.1016/j.vaccine.2013.10.068. Epub 2013 Nov 1.

PMID:
24188759
19.

Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis.

Breteler JK, Tam JS, Jit M, Ket JC, De Boer MR.

Vaccine. 2013 Oct 25;31(45):5168-77. doi: 10.1016/j.vaccine.2013.08.056. Epub 2013 Sep 5. Review.

PMID:
24012574
20.

Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Jackson CH, Jit M, Sharples LD, De Angelis D.

Med Decis Making. 2015 Feb;35(2):148-61. doi: 10.1177/0272989X13493143. Epub 2013 Jul 25.

PMID:
23886677
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk